Does Progyny Stock Lead the Pack?
Progyny‘s stock has significantly outperformed over the past year, with a 95% return, but how does its growth and profitability stack up against healthcare peers like Stryker and Zimmer Biomet? A closer look reveals robust revenue growth of 11.41% LTM and competitive free cash flow margins of 15.25% LTM. However, its 6.77% LTM operating margin trails some larger rivals, and its valuation (P/E 40.78) is considered moderate to high, suggesting limited upside if growth slows.
- PGNY’s 6.8% operating margin trails SYK’s 19.6%, reflecting a service model’s lower profitability vs. device sales.
- PGNY’s 11.4% revenue growth outpaces most peers, indicating robust demand for its fertility benefits, though GMED leads.
- PGNY gained 94.8% (PE 40.8), outperforming peers; market bets on strong future earnings and its expanding fertility market leadership.
Here’s how Progyny stacks up across size, valuation, and profitability versus key peers.
| PGNY | SYK | ZBH | GMED | PTON | OFIX | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.3 | 137.7 | 17.6 | 11.2 | 2.9 | 0.6 |
| Revenue ($ Bil) | 1.3 | 24.4 | 8.0 | 2.8 | 2.5 | 0.8 |
| PE Ratio | 40.8 | 46.8 | 21.8 | 26.5 | -28.3 | -4.8 |
| LTM Revenue Growth | 11.4% | 11.0% | 5.5% | 11.7% | -8.7% | 4.3% |
| LTM Operating Margin | 6.8% | 19.6% | 18.7% | 15.7% | 3.9% | -11.6% |
| LTM FCF Margin | 15.2% | 16.7% | 17.6% | 20.6% | 15.5% | -0.4% |
| 12M Market Return | 94.8% | -6.8% | -20.5% | 3.1% | -7.9% | -20.4% |
For more details on Progyny, read Buy or Sell PGNY Stock. Below we compare PGNY’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PGNY | 11.4% | – | 7.2% | 38.3% | 57.2% |
| SYK | 11.0% | – | 10.2% | 11.1% | 7.8% |
| ZBH | 5.5% | – | 3.8% | 6.5% | 1.6% |
| GMED | 11.7% | – | 60.6% | 53.3% | 6.8% |
| PTON | -8.7% | -7.8% | -3.6% | -21.8% | |
| OFIX | 4.3% | – | 7.1% | 62.1% | -0.8% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PGNY | 6.8% | – | 5.8% | 5.7% | 3.0% |
| SYK | 19.6% | – | 20.7% | 19.1% | 16.9% |
| ZBH | 18.7% | – | 19.9% | 19.6% | 17.2% |
| GMED | 15.7% | – | 8.7% | 12.9% | 23.1% |
| PTON | 3.9% | 2.5% | -15.0% | -30.8% | |
| OFIX | -11.6% | – | -9.7% | -19.0% | -6.3% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PGNY | 40.8 | – | 29.0 | 56.9 | 94.6 |
| SYK | 46.8 | – | 45.8 | 35.9 | 39.2 |
| ZBH | 21.8 | – | 23.7 | 24.8 | 115.5 |
| GMED | 26.5 | – | 109.0 | 49.0 | 39.2 |
| PTON | -28.3 | -28.5 | -4.0 | -2.2 | |
| OFIX | -4.8 | – | -5.3 | -3.3 | -20.8 |
Still not sure about PGNY stock? Consider portfolio approach.
Stock Picking Falls Short Against Multi Asset Portfolios
Individual picks are volatile but diversified assets offset each other. A multi asset portfolio helps you stay the course capture upside and reduce downside.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices